Patrizia Chetoni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9474726/publications.pdf

Version: 2024-02-01

85 papers

3,260 citations

33 h-index 54 g-index

90 all docs 90 docs citations

90 times ranked 3361 citing authors

#	Article	IF	Citations
1	Nanostructured Drug Delivery Systems for Targeting $5-\hat{l}_{\pm}$ -Reductase Inhibitors to the Hair Follicle. Pharmaceutics, 2022, 14, 286.	4.5	7
2	Hydrogels as Corneal Stroma Substitutes for In Vitro Evaluation of Drug Ocular Permeation. Pharmaceutics, 2022, 14, 850.	4.5	2
3	Ciclopirox Hydroxypropyl Chitosan (CPX-HPCH) Nail Lacquer and Breathable Cosmetic Nail Polish: In Vitro Evaluation of Drug Transungual Permeation Following the Combined Application. Life, 2022, 12, 801.	2.4	O
4	Combination of Nanomicellar Technology and In Situ Gelling Polymer as Ocular Drug Delivery System (ODDS) for Cyclosporine-A. Pharmaceutics, 2021, 13, 192.	4.5	18
5	Tyrosol-Enriched Tomatoes by Diffusion across the Fruit Peel from a Chitosan Coating: A Proposal of Functional Food. Foods, 2021, 10, 335.	4.3	6
6	Polyvinyl alcohol/cellulose hydrogel as possible corneal stroma substitute in drug permeation tests. Biomedical Science and Engineering, 2021, 4, .	0.0	0
7	A hybrid ocular delivery system of cyclosporine-A comprising nanomicelle-laden polymeric inserts with improved efficacy and tolerability. Biomaterials Science, 2021, 9, 8235-8248.	5.4	17
8	Ocular Application of Oleuropein in Dry Eye Treatment: Formulation Studies and Biological Evaluation. Pharmaceuticals, 2021, 14, 1151.	3.8	2
9	pH-Responsive Nanostructures Based on Surface Active Fatty Acid-Protic Ionic Liquids for Imiquimod Delivery in Skin Cancer Topical Therapy. Pharmaceutics, 2020, 12, 1078.	4.5	51
10	Reconstituted epithelial corneal tissues for evaluation of drug delivery. Biomedical Science and Engineering, 2020, 3, .	0.0	0
11	Reconstituted epithelial tissues and native cornea: A comparison of the influence of surfactants on ocular permeability. Biomedical Science and Engineering, 2020, 3, .	0.0	1
12	Assembling Surfactants-Mucoadhesive Polymer Nanomicelles (ASMP-Nano) for Ocular Delivery of Cyclosporine-A. Pharmaceutics, 2020, 12, 253.	4.5	33
13	Development and Characterization of a Novel Peptide-Loaded Antimicrobial Ocular Insert. Biomolecules, 2020, 10, 664.	4.0	14
14	Formulations Based on Natural Ingredients for the Treatment of Nail Diseases. Current Pharmaceutical Design, 2020, 26, 556-565.	1.9	3
15	Influence of a Combination of Chemical Enhancers and Iontophoresis on In Vitro Transungual Permeation of Nystatin. AAPS PharmSciTech, 2018, 19, 1574-1581.	3.3	19
16	Freeze-dried matrices for ocular administration of bevacizumab: a comparison between subconjunctival and intravitreal administration in rabbits. Drug Delivery and Translational Research, 2018, 8, 461-472.	5.8	14
17	A water-soluble, mucoadhesive quaternary ammonium chitosan-methyl- \hat{l}^2 -cyclodextrin conjugate forming inclusion complexes with dexamethasone. Journal of Materials Science: Materials in Medicine, 2018, 29, 42.	3.6	26
18	Effect of 5-Oxo-2-Pyrrolidinecarboxylic Acid (PCA) as a New Topically Applied Agent for Dry Eye Syndrome Treatment. Pharmaceutics, 2018, 10, 137.	4.5	10

#	Article	IF	CITATIONS
19	Development and Validation of an HPLC–UV Method to Quantify Tavaborole During in Vitro Transungual Permeation Studies. Journal of AOAC INTERNATIONAL, 2018, 101, 437-443.	1.5	7
20	Cutaneous Permeation and Penetration of Sunscreens: Formulation Strategies and In Vitro Methods. Cosmetics, 2018, 5, 1.	3.3	85
21	Ionic liquids as potential enhancers for transdermal drug delivery. International Journal of Pharmaceutics, 2017, 516, 45-51.	5.2	101
22	Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 109, 214-223.	4.3	121
23	$4\hat{a}$ €Methylbenzylidene camphor microspheres: reconstituted epidermis (Skinethic ^{\hat{A}®}) permeation and distribution. International Journal of Cosmetic Science, 2015, 37, 298-305.	2.6	10
24	Mucoadhesive nano-sized supramolecular assemblies for improved pre-corneal drug residence time. Drug Development and Industrial Pharmacy, 2015, 41, 2069-2076.	2.0	40
25	Liposomes as a potential ocular delivery system of distamycin A. International Journal of Pharmaceutics, 2015, 492, 120-126.	5.2	39
26	<i>In vitro</i> evaluation of some parameters involved in mucoadhesion of aqueous polymeric dispersions. Pharmaceutical Development and Technology, 2015, 20, 927-934.	2.4	10
27	Topical Formulations Containing Finasteride. Part II: Determination of Finasteride Penetration into Hair Follicles using the Differential Stripping Technique. Journal of Pharmaceutical Sciences, 2014, 103, 2323-2329.	3.3	15
28	Topical Formulations Containing Finasteride. Part I: In Vitro Permeation/Penetration Study and In Vivo Pharmacokinetics in Hairless Rat. Journal of Pharmaceutical Sciences, 2014, 103, 2307-2314.	3.3	24
29	Ciclopirox vs amorolfine: in vitro penetration into and permeation through human healthy nails of commercial nail lacquers. Journal of Drugs in Dermatology, 2014, 13, 143-7.	0.8	13
30	Nonpolymeric nanoassemblies for ocular administration of acyclovir: Pharmacokinetic evaluation in rabbits. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 80, 39-45.	4.3	24
31	Arabinogalactan as Active Compound in the Management of Corneal Wounds: In Vitro Toxicity and In Vivo Investigations on Rabbits. Current Eye Research, 2011, 36, 21-28.	1.5	23
32	Vehicle effects in ophthalmic bioavailability: An evaluation of polymeric inserts containing pilocarpine. Journal of Pharmacy and Pharmacology, 2011, 36, 229-234.	2.4	36
33	Validation of bovine hoof slices as a model for infected human toenails: in vitro ciclopirox transungual permeation. British Journal of Dermatology, 2011, 165, 99-105.	1.5	56
34	Permeation and Distribution of Ferulic Acid and Its \hat{i} ±-Cyclodextrin Complex from Different Formulations in Hairless Rat Skin. AAPS PharmSciTech, 2011, 12, 514-520.	3.3	35
35	Poloxamer 407 microspheres for orotransmucosal drug delivery. Part II: In vitro/in vivo evaluation. International Journal of Pharmaceutics, 2010, 400, 32-36.	5.2	33
36	Poloxamer 407 microspheres for orotransmucosal drug delivery. Part I: Formulation, manufacturing and characterization. International Journal of Pharmaceutics, 2010, 399, 71-79.	5.2	29

#	Article	IF	CITATIONS
37	Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity. British Journal of Dermatology, 2010, 162, 311-317.	1.5	54
38	Optimization of skin permeation and distribution of ibuprofen by using nanostructures (coagels) based on alkyl vitamin C derivatives. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 443-449.	4.3	26
39	Niaouli oils from different sources: Analysis and influence on cutaneous permeation of estradiol in vitro. Drug Delivery, 2009, 16, 237-242.	5.7	12
40	Skin Permeation and Distribution of Two Sunscreens: A Comparison between Reconstituted Human Skin and Hairless Rat Skin. Skin Pharmacology and Physiology, 2008, 21, 318-325.	2.5	20
41	Healing of rabbits' cornea following laser welding: effect of solid and semisolid formulations containing indocyanine green. Journal of Drug Delivery Science and Technology, 2007, 17, 25-31.	3.0	7
42	Larch Arabinogalactan for Dry Eye Protection and Treatment of Corneal Lesions: Investigations in Rabbits. Journal of Ocular Pharmacology and Therapeutics, 2007, 23, 541-550.	1.4	27
43	Ophthalmic delivery systems based on drug–polymer–polymer ionic ternary interaction: In vitro and in vivo characterization. European Journal of Pharmaceutics and Biopharmaceutics, 2006, 62, 59-69.	4.3	39
44	Rufloxacin Eyedrops: Effect of Different Formulations on Ocular Pharmacokinetics in Rabbits. European Journal of Ophthalmology, 2006, 16, 311-317.	1.3	8
45	Effect of Permeation Enhancers on Buccal Absorption. Arzneimittelforschung, 2006, 56, 561-567.	0.4	5
46	In Vitro Transungual Permeation of Ciclopirox from a Hydroxypropyl Chitosan-Based, Water-Soluble Nail Lacquer. Drug Development and Industrial Pharmacy, 2005, 31, 11-17.	2.0	68
47	Effects of Different N-Trimethyl Chitosans on In Vitro/In Vivo Ofloxacin Transcorneal Permeation. Journal of Pharmaceutical Sciences, 2004, 93, 2851-2862.	3.3	83
48	Development of Cultured Rabbit Corneal Epithelium for Drug Permeation Studies: A Comparison with Excised Rabbit Cornea. Journal of Ocular Pharmacology and Therapeutics, 2004, 20, 518-532.	1.4	14
49	Comparison of Liposome-Encapsulated Acyclovir with Acyclovir Ointment: Ocular Pharmacokinetics in Rabbits. Journal of Ocular Pharmacology and Therapeutics, 2004, 20, 169-177.	1.4	52
50	PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: in vitro/in vivo studies. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 57, 207-212.	4.3	134
51	Carrageenan–gelatin mucoadhesive systems for ion-exchange based ophthalmic delivery: in vitro and preliminary in vivo studies. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 57, 465-472.	4.3	74
52	Effect of iontophoresis on transcorneal permeation â€~in vitro' of two β-blocking agents, and on corneal hydration. International Journal of Pharmaceutics, 2003, 250, 423-429.	5.2	30
53	Ocular toxicity of some corneal penetration enhancers evaluated by electrophysiology measurements on isolated rabbit corneas. Toxicology in Vitro, 2003, 17, 497-504.	2.4	50
54	A Collaborative Evaluation of the Cytotoxicity of Two Surfactants by Using the Human Corneal Epithelial Cell Line and the WST-1 Test. Journal of Ocular Pharmacology and Therapeutics, 2003, 19, 11-21.	1.4	18

#	Article	IF	CITATIONS
55	Increased corneal hydration induced by potential ocular penetration enhancers: assessment by differential scanning calorimetry (DSC) and by desiccation. International Journal of Pharmaceutics, 2002, 232, 139-147.	5.2	72
56	Effect of different terpene-containing essential oils on permeation of estradiol through hairless mouse skin. International Journal of Pharmaceutics, 2002, 237, 209-214.	5.2	61
57	Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. International Journal of Pharmaceutics, 2002, 238, 241-245.	5.2	343
58	Formulation and Preliminary in vivo Testing of Rufloxacin-Cyclodextrin Ophthalmic Solutions. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2002, 44, 173-176.	1.6	10
59	Cytotoxicity of potential ocular permeation enhancers evaluated on rabbit and human corneal epithelial cell lines. Toxicology Letters, 2001, 122, 1-8.	0.8	84
60	Gel-forming erodible inserts for ocular controlled delivery of ofloxacin. International Journal of Pharmaceutics, 2001, 215, 101-111.	5 . 2	62
61	Relevance of polymer molecular weight to the in vitro/in vivo performances of ocular inserts based on poly(ethylene oxide). International Journal of Pharmaceutics, 2001, 220, 169-177.	5.2	30
62	Comparison of the effect of ultrasound and of chemical enhancers on transdermal permeation of caffeine and morphine through hairless mouse skin in vitro. International Journal of Pharmaceutics, 2001, 229, 131-137.	5 . 2	41
63	Albumin Microspheres for Ocular Delivery of Piroxicam. Pharmacy and Pharmacology Communications, 2000, 6, 149-153.	0.3	14
64	Xyloglucan as a Novel Vehicle for Timolol: Pharmacokinetics and Pressure Lowering Activity in Rabbits. Journal of Ocular Pharmacology and Therapeutics, 2000, 16, 497-509.	1.4	54
65	Pharmacokinetics and Anti-Inflammatory Activity in Rabbits of a Novel Indomethacin Ophthalmic Solution. Journal of Ocular Pharmacology and Therapeutics, 2000, 16, 363-372.	1.4	25
66	Prolonged, Contemporaneous Administration of Pilocarpine and Timolol Increases the Aqueous Humor Pilocarpine Levels in Rabbits. Journal of Ocular Pharmacology and Therapeutics, 1999, 15, 1-7.	1.4	0
67	Pectin microspheres as ophthalmic carriers for piroxicam: evaluation in vitro and in vivo in albino rabbits. European Journal of Pharmaceutical Sciences, 1999, 9, 1-7.	4.0	72
68	Development of a Simple Dry Eye Model in the Albino Rabbit and Evaluation of Some Tear Substitutes. Ophthalmic Research, 1999, 31, 229-235.	1.9	103
69	Ocular Bioadhesive Drug Delivery Systems. Drugs and the Pharmaceutical Sciences, 1999, , 601-640.	0.1	9
70	Silicone rubber/hydrogel composite ophthalmic inserts: preparation and preliminary in vitro/in vivo evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 1998, 46, 125-132.	4.3	38
71	Effect of Suleparoide on Fibrinolysis in the Anterior Chamber of Rabbits. Ophthalmic Research, 1996, 28, 176-183.	1.9	1
72	Evaluation of ocular permeation enhancers: In vitro effects on corneal transport of four \hat{l}^2 -blockers, and in vitro/in vivo toxic activity. International Journal of Pharmaceutics, 1996, 142, 103-113.	5 . 2	120

#	Article	IF	Citations
73	Ocular Mini-Tablets for Controlled Release of Timolol: Evaluation in Rabbits. Journal of Ocular Pharmacology and Therapeutics, 1996, 12, 245-252.	1.4	10
74	Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion pair. International Journal of Pharmaceutics, 1995, 117, 243-246.	5.2	69
75	Albuterol prodrugs for ocular administration: synthesis and evaluation of the physico-chemical and IOP-depressant properties of three albuterol triesters. International Journal of Pharmaceutics, 1994, 105, 147-155.	5.2	6
76	Mucoadhesive Ophthalmic Vehicles: Evaluation of Polymeric Low-Viscosity Formulations. Journal of Ocular Pharmacology and Therapeutics, 1994, 10, 83-92.	1.4	63
77	Influence of Drug Release Rate on Systemic Timolol Absorption from Polymeric Ocular Inserts in the Pigmented Rabbit. Journal of Ocular Pharmacology and Therapeutics, 1994, 10, 421-429.	1.4	11
78	Preparation and evaluation in vitro of solutions and o/w microemulsions containing levobunolol as ion-pair. International Journal of Pharmaceutics, 1993, 100, 219-225.	5.2	29
79	Intraocular Pressure Reduction and Systemic Absorption of Timolol After Administration of One Side-Coated Inserts in Rabbits. Journal of Ocular Pharmacology and Therapeutics, 1993, 9, 1-12.	1.4	3
80	Preliminary Evaluation of a Series of Amphiphilic Timolol Prodrugs: Possible Evidence for Transscleral Absorption. Journal of Ocular Pharmacology and Therapeutics, 1993, 9, 141-150.	1.4	14
81	Release of miconazole from topical PVA matrices: preliminary in vitro and in vivo data. Journal of Controlled Release, 1991, 16, 197-202.	9.9	1
82	Evaluation of high- and low-molecular-weight fractions of sodium hyaluronate and an ionic complex as adjuvants for topical ophthalmic vehicles containing pilocarpine. International Journal of Pharmaceutics, 1991, 72, 131-139.	5.2	63
83	Muco-Adhesive Liquid Ophthalmic Vehicles - Evaluation of Macromolecular Ionic Complexes of Pilocarpine. Drug Development and Industrial Pharmacy, 1989, 15, 2475-2489.	2.0	21
84	Evaluation of muco-adhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid. International Journal of Pharmaceutics, 1989, 51, 203-212.	5.2	142
85	Arabinogalactan: a new ophthalmic vehicle for dry eye protection and treatment of corneal lesions. Acta Ophthalmologica, 0, 85, 0-0.	0.3	0